ALB and head and neck squamous cell carcinoma: A single-arm, multi-center, phase II trial indicated superior objective response rate and OS with albumin-bound paclitaxel, cetuximab, and carboplatin (CACTUX) as compared to the EXTREME regimen in patients afflicted with R/M HNSCC (179).